the following examples set forth preferred materials and procedures in accordance with the present invention , it is to be understood , however , that these examples are provided by way of illustration only , and nothing therein should be deemed a limitation upon the overall , scope of the invention . this example compares the relative yields of orf2 using methods of the present , invention with methods that are known in the prior art . four 1000 ml spinner flasks were each seeded with approximately 1 . 0 × 10 6 sf + cells / ml in 300 ml of insect serum free media , excell 420 ( jrh biosciences , inc ., lenexa , kans .). the master cell culture is identified as sf +( spodoptera frugiperda ) master cell stock , passage 19 , lot ™ n112 - 095w . the cells used to generate the sf + master cell stock were obtained from protein sciences corporation , inc . meriden , conn . the sf + cell line for this example was confined between passages 19 and 59 . other passages will work for purposes of the present invention , but in order to scale the process up for large scale production , at least 19 passages will probably be necessary and passages beyond 59 may have an effect on expression , although this was not investigated . in more detail , the initial sf + cell cultures from liquid nitrogen storage were grown in excell 420 media in suspension in sterile spinner flasks with constant agitation . the cultures were grown in 100 ml to 250 ml spinner flasks with 25 to 150 ml of excell 420 serum - free media . when the cells had multiplied to a cell density of 1 . 0 - 8 . 0 × 10 6 cells / ml , they were split to new vessels with a planting density of 0 . 5 - 1 . 5 × 10 6 cells / ml , subsequent expansion cultures were grown in spinner flasks up to 36 liters in size or in stainless steel bioreactors of up to 300 liters for a period of 2 - 7 days at 25 - 29 ° c . after seeding , the flasks were incubated at 27 ° c . for four hours . subsequently , each flask was seeded with a recombinant baculovirus containing the pcv2 orf2 gene ( seq id no : 4 ). the recombinant baculovirus containing the pcv2 orf2 gene was generated as follows : the pcv2 orf2 gene from a north american strain of pcv2 was pcr amplified to contain a 5 ′ kodak &# 39 ; s sequence ( seq id no : 1 ) and a 3 ′ ecor1 site ( seq id no : 2 ), cloned into the pgem - t - easy vector ( promega , madison . wi ). then , it was subsequently excised and subcloned into the transfer vector pvl1392 ( bd biosciences pharmingen , san diego , calif .). the subcloned portion is represented herein as seq id no : 7 . the pvl1392 plasmid containing the pcv2 orf2 gene was designated n47 - 064y and then co - transfected with baculogold ® ( bd biosciences pharmingen ) baculovirus dna into sf + insect cells ( protein sciences . meriden , conn .) to generate the recombinant baculovirus containing the pcv2 orf2 gene . the new construct is provided herein as seq id no : 8 . the recombinant baculovirus containing the pcv2 orf2 gene was plaque - purified and master seed virus ( msv ) was propagated on the sf + cell line , aliquotted , and stored at − 70 ° c . the msv was positively identified as pcv2 orf2 baculovirus by pcr - rflp using baculovirus specific primers . insect cells infected with pcv2 orf2 baculovirus to generate msv or working seed virus express pcv2 orf2 antigen as detected by polyclonal serum or monoclonal antibodies in an indirect fluorescent antibody assay . additionally , the identity of the pcv2 orf2 baculovirus was confirmed by n - terminal amino acid sequencing . the pcv2 orf2 baculovirus msv was also tested for purity in accordance with 9 c . f . r . 113 . 27 ( c ), 113 . 28 , and 113 . 55 . each recombinant baculovirus seeded into the spinner flasks had varying multiplicities of infection ( mois ). flask 1 was seeded with 7 . 52 ml of 0 . 088 moi seed ; flask 2 was seeded with 3 . 01 ml of 0 . 36 moi seed ; flask 3 was seeded with 1 . 5 ml of 0 . 18 moi seed ; and flask 4 was seeded with 0 . 75 ml of 0 . 09 moi seed . a schematic flow diagram illustrating the basic steps used to construct a pcv2 orf2 recombinant baculovirus is provided herein as fig1 . after being seeded with the baculovirus , the flasks were then incubated at 27 ± 2 ° c . for 7 days and were also agitated at 100 rpm during that time . the flasks used ventilated caps to allow for air flow . samples from each flask were taken every 24 hours for the next 7 days . after extraction , each sample was centrifuged , and both the pellet and the supernatant were separated and then microfiltered through a 0 . 45 - 1 . 0 μm pore size membrane . the resulting samples then had the amount of orf2 present within them quantified via an elisa assay . the elisa assay was conducted with capture antibody swine anti - pcv2 pab igg prot . g purified ( diluted 1 : 250 in pbs ) diluted to 1 : 6000 in 0 . 05m carbonate buffer ( ph 9 . 6 ). 100 μl of the antibody was then placed in the wells of the mictrotiter plate , sealed , and incubated overnight at 37 ° c . the plate was then washed three times with a wash solution which comprised 0 . 5 ml of tween 20 ( sigma , st . louis , mo . ), 100 ml of 10 × d - pbs ( gibco invitrogen , carlsbad , calif .) and 899 . 5 ml of distilled water . subsequently , 250 μl of a blocking solution ( 5 g carnation non - fat dry milk ( nestle , glendale , calif .) in 10 ml of d - pbs qs to 100 ml with distilled water ) was added to each of the wells . the next step was to wash the test , plate and then add pre - diluted antigen . the pre - diluted antigen was produced by adding 200 μl of diluent solution ( 0 . 5 ml tween 20 in 999 . 5 ml d - pbs ) to each of the wells on a dilution plate . the sample was then diluted at a 1 : 240 ratio and a 1 : 480 ratio , and 100 μl of each of these diluted samples was then added to one of the top wells on the dilution plate ( i . e . one top well received 100 μl of the 1 . 240 dilution and the other received 100 μl of the 1 : 480 dilution ). serial dilutions were then done for the remainder of the plate by removing 100 μl form each successive well and transferring it to the next well on the plate . each well was mixed prior to doing the next transfer . the test plate washing included washing the plate three times with the wash buffer . the plate was then sealed and incubated for an hour at 37 ° c . before being washed three more times with the wash buffer . the detection antibody used was monoclonal antibody to pcv orf2 . it was diluted to 1 : 300 in diluent solution , and 100 μl of the diluted detection antibody was then added to the wells . the plate was then sealed and incubated for an hour at 37 ° c . before being washed three times with the wash buffer . conjugate diluent was then prepared by adding normal rabbit serum ( jackson immunoresearch . west grove , pa .) to the diluent solution to 1 % concentration . conjugate antibody goat anti - mouse ( h + i )- hrp ( jackson immunoresearch ) was diluted in the conjugate diluent to 1 : 10 , 000 . 100 μl of the diluted conjugate antibody was then added to each of the wells . the plate was then sealed and incubated for 45 minutes at 37 ° c . before being washed three times with the wash buffer . 100 μl of substrate ( tmb peroxidase substrate , kirkgaard and perry laboratories ( kpl ), gaithersberg , md . ), mixed with an equal volume of peroxidase substrate b ( kpl ) was added to each of the wells . the plate was incubated at room temperature for 15 minutes . 100 μl of 1n hcl solution was then added to all of the wells to stop the reaction . the plate was then run through an elisa reader . the results of this assay are provided in table 1 below : these results indicate that when the incubation time is extended , expression of orf2 into the supernatant of the centrifuged cells and media is greater than expression in the pellet of the centrifuged cells and media . accordingly , allowing the orf2 expression to proceed for at least 5 days and recovering it in the supernate rather than allowing expression to proceed for less than 5 days and recovering orf2 from the cells , provides a great increase in orf2 yields , and a significant improvement over prior methods . this example provides data as to the efficacy of the invention claimed herein . a 1000 ml spinner flask was seeded with approximately 1 . 0 × 10 6 sf + cells / ml in 300 ml of excell 420 media . the flask was then incubated at 27 ° c . and agitated at 100 rpm . subsequently , the flask was seeded with 10 ml of pcv2 orf2 / bac p + 6 ( the recombinant baculovirus containing the pcv2 orf2 gene passaged 6 additional times in the sf9 insect cells ) virus seed with a 0 . 1 moi after 24 hours of incubation . the flask was then incubated at 27 ° c . for a total of 6 days . after incubation , the flask was then centrifuged and three samples of the resulting supernatant were harvested and inactivated . the supernatant was inactivated by bringing its temperature to 37 ± 2 ° c . to the first sample , a 0 . 4m solution of 2 - bromoethyleneamine hydrobromide which had been cyclized to 0 . 2m binary ethlylenimine ( bei ) in 0 . 3n naoh is added to the supernatant to give a final concentration of bei of 5 mm . to the second sample , 10 mm bei was added to the supernatant . to the third sample , no bei was added to the supernatant . the samples were then stirred continuously for 48 hrs . a 1 . 0 m sodium thiosulfate solution to give a final minimum concentration of 5 mm was added to neutralize any residual bei . the quantify of orf2 in each sample was then quantified using the same elisa assay procedure as described in example 1 . the results of this may be seen in table 2 below : this example demonstrates that neutralization with bei does not remove or degrade significant amounts of the recombinant pcv2 orf2 protein product . this is evidenced by the fact that there is no large loss of orf2 in the supernatant from the bei or elevated temperatures . those of skill in the art will recognize that the recovered orf2 is a stable protein product . this example demonstrates that the present invention is scalable from small scale production of recombinant pcv2 orf2 to large scale production of recombinant pcv2 orf2 . 5 . 0 × 10 5 cells / ml of sf + cells / ml in 7000 ml of excell 420 media was planted in a 20000 ml applikon bioreactor . the media and cells were then incubated at 27 ° c . and agitated at 100 rpm for the next 68 hours . at the 68 th hour , 41 . 3 ml of pcv2 orf2 baculovirus msv + 3 was added to 7000 ml of excell 420 medium . the resultant mixture was then added to the bioreactor . for the next seven days , the mixture was incubated at 27 ° c . and agitated at 100 rpm . samples from the bioreactor were extracted every 24 hours beginning at day 4 , post - infection , and each sample was centrifuged . the supernatant of the samples were preserved and the amount of orf2 was then quantified using sds - page densitometry . the results of this can be seen in table 3 below : this example tests the efficacy of seven pcv2 candidate vaccines and further defines efficacy parameters following exposure to a virulent strain of pcv2 . one hundred and eight ( 108 ) cesarean derived colostrum deprived ( cdcd ) piglets , 9 - 14 days of age , were randomly divided into 9 groups of equal size . table 4 sets forth the general study design for this example . seven of the groups ( groups 1 - 7 ) received doses of pcv2 orf2 poly peptide , one of the groups acted as a challenge control and received no pcv2 orf2 , and another group acted as the strict negative control group and also received no pcv2 orf2 . on day 0 , groups 1 through 7 were treated with assigned vaccines . piglets in group 7 were given a booster treatment on day 14 . piglets were observed for adverse events and injection site reactions following vaccination and on day 19 , piglets were moved to the second study site . at the second study site , groups 1 - 8 were group housed in one building while group 9 was housed in a separate building . all pigs received keyhole limpet hemocyanin ( klh )/ incomplete freund &# 39 ; s adjuvant ( icfa ) on days 21 and 27 and on day 24 , groups 1 - 8 were challenged with a virulent pcv2 . pre - and post - challenge , blood samples were collected for pcv2 serology . post - challenge , body weight data for determination of average daily weight gain ( adwg ), and clinical symptoms , as well as nasal swab samples to determine nasal shedding of pcv2 , were collected . on day 49 , all surviving pigs were necropsied , lungs were scored for lesions , and selected tissues were preserved in formalin for immunohistochemistry ( ihc ) testing at a later date . this was a partially blinded vaccination - challenge feasibility study conducted in cdcd pigs , 9 to 14 days of age on day 0 . to be included in the study . pcv2 ifa titers of sows were ≧ 1 : 1000 . additionally , the serologic status of sows were from a known prrs - negative herd . twenty - eight ( 28 ) sows were tested for pcv 2 serological status . fourteen ( 14 ) sows had a pcv2 titer of ≧ 1000 and were transferred to the first study site . one hundred ten ( 110 ) piglets were delivered by cesarean section surgeries and were available for this study on day − 4 . on day − 3 , 108 cdcd pigs at the first study site were weighed , identified with ear tags , blocked by weight and randomly assigned to 1 of 9 groups , as set forth above in table 4 . if any test animal meeting the inclusion criteria was enrolled in the study and was later excluded for any reason , the investigator and monitor consulted in order to determine the use of data collected from the animal in the final analysis . the date of which enrolled piglets were excluded and the reason for exclusion was documented . initially , no sows were excluded . a total of 108 of an available 110 pigs were randomly assigned to one of 9 groups on day − 3 . the two smallest pigs ( no . 17 and 19 ) were not assigned to a group and were available as extras , if needed . during the course of the study , several animals were removed . pig 82 ( group 9 ) on day − 1 , pig no . 56 ( group 6 ) on day 3 , pig no . 53 ( group 9 ) on day 4 , pig no . 28 ( group 8 ) on day 8 , pig no . 69 ( group 8 ) on day 7 , and pig no . 93 ( group 4 ) on day 9 , were each found dead prior to challenge . these six pigs were not included in the final study results . pig no 17 ( one of the extra pigs ) was assigned to group 9 . the remaining extra pig . no . 19 , was excluded from the study . the formulations given to each of the groups were as follows : group 1 was designed to administer 1 ml of viral orf2 ( vorf2 ) containing 16 μg orf2 / ml . this was done by mixing 10 . 24 ml of viral orf2 ( 256 μg / 25 μg / ml = 10 . 24 ml vorf2 ) with 3 . 2 ml of 0 . 5 % carbopol and 2 . 56 ml of phosphate buffered saline at a ph of 7 . 4 . this produced 1 . 6 ml of formulation for group 1 . group 2 was designed to administer 1 ml of orf2 containing 8 μg vorf2 / ml . this was done by mixing 5 . 12 ml of vorf2 ( 128 μg / 25 μg / ml = 5 . 12 ml vorf2 ) with 3 . 2 ml of 0 . 5 % carbopol and 7 . 68 ml of phosphate buffered saline at a ph of 7 . 4 . this produced 16 ml of formulation for group 2 . group 3 was designed to administer 1 ml of vorf2 containing 4 μg vorf2 / ml . this was done by mixing 2 . 56 ml of vorf2 ( 64 μg / 25 μg / ml = 2 . 56 ml vorf2 ) with 3 . 2 ml of 0 . 5 % carbopol and 10 . 24 ml of phosphate buffered saline at a ph of 7 . 4 . this produced 16 ml of formulation for group 3 . group 4 was designed to administer 1 ml of recombinant orf2 ( rorf2 ) containing 16 μg rorf2 / ml . this was done by mixing 2 . 23 ml of rorf2 ( 5 . 12 μg / 230 μg / ml = 2 . 23 ml rorf2 ) with 6 . 4 ml of 0 . 5 % carbopol and 23 . 37 ml of phosphate buffered saline at a ph of 7 . 4 . this produced 32 ml of formulation for group 4 . group 5 was designed to administer 0 . 1 ml of rorf2 containing 8 μg rorf2 / ml . this was done by mixing 1 . 11 ml of rorf2 ( 256 μg / 230 μg / ml = 1 . 11 ml rorf2 ) with 6 . 4 ml of 0 . 5 % carbopol and 24 . 49 ml of phosphate buffered saline at a ph of 7 . 4 . this produced 32 ml of formulation for group 5 . group 6 was designed to administer 1 ml of rorf2 containing 8 μg rorf2 / ml . this was done by mixing 0 . 56 ml of rorf2 ( 128 μg / 230 μg / ml = 0 . 56 ml rorf2 ) with 6 . 4 ml of 0 . 5 % carbopol and 25 . 04 ml of phosphate buffered saline at a ph of 7 . 4 . this produced 32 ml of formulation for group 6 . group 7 was designed to administer 2 ml of pcv2 whole killed cell vaccine ( pcv2 kv ) containing the max pcv2 kv . this was done by mixing 56 ml of pcv2 kv with 14 ml of 0 . 5 % carbopol . this produced 70 ml of formulation for group 7 . finally group 8 was designed to administer klh at 0 . 5 μg / ml or 1 . 0 μg / ml per 2 ml dose . this was done by mixing 40 . 71 ml klh ( 7 . 0 μg protein / ml at 0 . 5 μg / ml = 570 ml ( 7 . 0 μg / ml )( x )= ( 0 . 5 )( 570 ml )), 244 . 29 ml phosphate buffered saline at a ph of 7 . 4 , and 285 ml freunds adjuvant . table 5 describes the time frames for the key activities of this example . following completion of the in - life phase of the study , formalin fixed tissues were examined by immunohistochemistry ( ihc ) for detection of pcv2 antigen by a pathologist ; blood samples were evaluated for pcv2 serology , nasal swab samples were evaluated for pcv2 shedding , and average daily weight gain ( adwg ) was determined from day 24 to day 49 . animals were housed at the first study site in individual cages in five rooms from birth to approximately 11 days of age ( approximately day 0 of the study ). each room was identical in layout and consisted of stacked individual stainless steel cages with heated and filtered air supplied separately to each isolation unit . each room had separate heat and ventilation , thereby preventing cross - contamination of air between rooms . animals were housed in two different buildings at the second study site . group 9 ( the strict negative control group ) was housed separately in a converted finisher building and groups 3 - 8 were housed in converted nursery building . each group was housed in a separate pen ( 1 . 1 - 12 pigs per pen ) and each pen provided approximately 3 . 0 square feet per pig . each pen was on an elevated deck with plastic slatted floors . a pit below the pens served as a holding tank for excrement and waste . each building had its own separate heating and ventilation systems , with little likelihood of cross - contamination of air between buildings . at the first study site , piglets were fed a specially formulated milk ration from birth to approximately 3 weeks of age . all piglets were consuming solid , special mixed ration by day 19 ( approximately 4½ weeks of age ). at the second study site , all piglets were fed a custom non - medicated commercial mix ration appropriate for their age and weight , ad libitum . wafer at both study sites was also available ad libitum . all test pigs were treated with vitamin e on day − 2 , with iron injections on day − 1 and with naxcel ® ( 1 . 0 ml , 1m , in alternating hams ) on days 16 , 17 , 18 and 19 . in addition . pig no . 52 ( group 9 ) was treated with an iron injection on day 3 , pig 45 ( group 6 ) was treated with an iron injection on day 11 , pig no . 69 ( group 8 ) was treated with naxcel ® on day 6 , pig no . 74 ( group 3 ) was treated with dexamethazone and penicillin on day 14 , and pig no . 51 ( group 1 ) was treated with dexamethazone and penicillin on day 13 and with naxcel ® on day 14 for various health reasons . while at both study sites , pigs were under veterinary care . animal health examinations were conducted on day 0 and were recorded on the health examination record form . all animals were in good health and nutritional status before vaccination as determined by observation on day 0 . all test animals were observed to be in good health and nutritional status prior to challenge . carcasses and tissues were disposed of by rendering . final disposition of study animals was records on the animal disposition record . on day 0 , pigs assigned to groups 1 - 6 received 1 . 0 ml of pcv2 vaccines 1 - 6 , respectively , 1m in the left neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × ½ ″ needle . pigs assigned to group 7 received 2 . 0 ml of pcv2 vaccine no . 7 im in the left neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × ½ needle . on day 14 , pigs assigned to group 7 received 2 . 0 ml of pcv2 vaccine no . 7 im in the right neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × w needle . on day 21 all test pigs received 2 . 0 ml of klh / icfa im in the right ham region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × 1 ″ needle . on day 27 all test pigs received 2 . 0 ml of klh / icfa in the left ham region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × 1 ″ needle . on day 24 , pigs assigned to groups 1 - 8 received 1 . 0 ml of pcv2 isuvdl challenge material ( 5 . 11 logic tcid 50 / ml ) 1m in the left neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × 1 ″ needle . an additional 1 . 0 ml of the same material was administered 1n to each pig ( 0 . 5 ml per nostril ) using a sterile 3 . 0 ml luer - lock syringe and nasal canula . test pigs were observed daily for overall health and adverse events on day − 4 and from day 0 to day 19 . observations were recorded on the clinical observation record . all test pigs were observed from day 0 to day 7 , and group 7 was further observed from day 14 to 21 , for injection site reactions . average daily weight gain was determined by weighing each pig on a calibrated scale on days − 3 , 24 and 49 , or on the day that a pig was found dead after challenge . body weights were recorded on the body weight form . day 3 body weights were utilized to block pigs prior to randomization . day 24 and day 49 weight data was utilized to determine the average daily weight gain ( adwg ) for each pig during these time points . for pigs that died after challenge and before day 49 , the adwg was adjusted to represent the adwg from day 24 to the day of death . in order to determine pcv2 serology , venous whole blood was collected from each piglet from the orbital venous sinus on days − 3 and 1 . 4 , for each piglet , blood was collected from the orbital venous sinus by inserting a sterile capillary tube into the medial canthus of one of the eyes and draining approximately 3 . 0 ml of whole blood into a 4 . 0 ml serum separator tube ( sst ). on days 24 , 31 , and 49 , venous whole blood from each pig was collected from the anterior vena cava using a sterile 18 g × 1½ ″ vacutainer needle ( becton dickinson and company , franklin lakes , n . j . ), a vacutainer needle holder and a 13 ml sst . blood collections at each time point were recorded on the sample collection record . blood in each sst was allowed to clot , each sst was then spun down and the serum harvested . harvested serum was transferred to a sterile snap tube and stored at − 70 ± 10 ° c . until tested at a later date . serum samples were tested for the presence of pcv2 antibodies by bivi - r & amp ; d personnel . pigs were observed once daily from day 20 to day 49 for clinical symptoms and clinical observations were recorded on the clinical observation record . to test for pcv2 nasal shedding , on days 24 , 25 , and then every other odd numbered study day up to and including day 49 , a sterile dacron swab was inserted intra nasally into either the left or right nostril of each pig ( one swab per pig ) as aseptically as possible , swished around for a few seconds and then removed . each swab was then placed into a single sterile snap - cap tube containing 1 . 0 ml of emem media with 2 % ifbs , 500 units / ml of penicillin , 500 μg / ml of streptomycin and 2 . 5 μg / ml of fungizone . the swab was broken off in the tube , and the snap tube was sealed and appropriately labeled with animal number , study number , date of collection , study day and “ nasal swab .” sealed snap tubes were stored at − 40 ± 10 ° c . until transported overnight on ice to bivi - st . joseph . nasal swab collections were recorded on the nasal swab sample collection form . bivi - r & amp ; d conducted quantitative virus isolation ( vi ) testing for pcv2 on nasal swab samples . the results were expressed in log 10 values . a value of 1 . 3 logs or less was considered negative and any value greater than 1 . 3 logs was considered positive . pigs that died ( nos . 28 , 52 , 56 , 69 , 82 , and 93 ) at the first study site were necropsied to the level necessary to determine a diagnosis . gross lesions were recorded and no tissues were retained from these pigs . at the second study site , pigs that died prior to day 49 ( nos . 45 , 23 , 58 , 35 ), pigs found dead on day 49 prior to euthanasia ( nos . 2 , 43 ) and pigs euthanized on day 49 were necropsied . any gross lesions were noted and the percentages of lung lobes with lesions were recorded on the necropsy report form . from each of the 103 pigs necropsied at the second study site , a tissue sample of tonsil , lung , heart , liver , mesenteric lymph node , kidney and inguinal lymph node was placed into a single container with buffered 10 % formalin ; while another tissue sample from the same aforementioned organs was placed into a whirl - pak ( m - tech diagnostics ltd ., thelwall , uk ) and each whirl - pak was placed on ice . each container was properly labeled . sample collections were recorded on the necropsy report form . afterwards , formalin - fixed tissue samples and a diagnostic request form were submitted for ihc testing . ihc testing was conducted in accordance with standard isu laboratory procedures for receiving samples , sample and slide preparation , and staining techniques . fresh tissues in whirl - paks were shipped with ice packs to the study monitor for storage (− 70 °± 10 ° c .) and possible future use . formalin - fixed tissues were examined by a pathologist for detection of pcv2 by ihc and scored using the following scoring system : 0 = none ; 1 = scant positive staining , few sites ; 2 = moderate positive staining , multiple sites ; and 3 = abundant positive staining , diffuse throughout the tissue . due to the fact that the pathologist could not positively differentiate inguinal ln from mesenteric ln , results for these tissues were simply labeled as lymph node and the score given the highest score for each of the two tissues per animal . results for this example are given below . it is noted that one pig from group 9 died before day 0 , and 5 more pigs died post - vaccination ( 1 pig from group 4 ; 1 pig from group 6 ; 2 pigs from group 8 ; and 1 pig from group 9 ). post - mortem examination indicated all six died due to underlying infections that were not associated with vaccination or pmws . additionally , no adverse events or injection site reactions were noted with any groups . average daily weight gain ( adwg ) results are presented below in table 6 , group 9 , the strict negative control group , had the highest adwg ( 1 . 06 ± 0 . 17 lbs / day ), followed by group 5 ( 0 . 94 ± 0 . 22 lbs / day ), which received one dose of 8 μg of rorf2 . group 3 , which received one dose of 4 μg of vorf2 , had the lowest adwg ( 0 . 49 ± 0 . 21 lbs / day ), followed by group 7 ( 0 . 50 ± 0 . 15 lbs / day ), which received 2 doses of killed vaccine pcv2 serology results are presented below in table 7 . all nine groups were seronegative for pcv2 on day − 3 . on day 14 , groups receiving vorf2 vaccines had the highest titers , which ranged from 187 . 5 to 529 . 2 . pigs receiving killed viral vaccine had the next highest titers , followed by the groups receiving rorf2 vaccines . groups 8 and 9 remained seronegative at this time . on day 24 and day 31 , pigs receiving vorf2 vaccines continued to demonstrate a strong serological response , followed closely by the group that received two doses of a killed viral vaccine . pigs receiving rorf2 vaccines were slower to respond serologically and groups 8 and 9 continued to remain seronegative . on day 49 , pigs receiving vorf2 vaccine , 2 doses of the killed viral vaccine and the lowest dose of rorf2 demonstrated the strongest serological responses . pigs receiving 16 μg and 8 μg of rorf2 vaccines had slightly higher ifa titers than challenge controls . group 9 on day 49 demonstrated a strong serological response . the results from the post - challenge clinical observations are presented below in table 8 . this summary of results includes observations for abnormal behavior , abnormal respiration , cough and diarrhea . table 9 includes the results from the summary of group overall incidence of clinical symptoms and table 10 includes results from the summary of group mortality rates post - challenge . the most common clinical symptom noted in this study was abnormal behavior , which was scored as mild to severe lethargy . pigs receiving the 2 lower doses of vorf2 , pigs receiving 16 μg of rorf2 and pigs receiving 2 doses of kv vaccine had incidence rates of ≧ 27 . 3 %. pigs receiving 8 μg of rorf2 and the strict negative control group had no abnormal behavior . none of the pigs in this study demonstrated any abnormal respiration . coughing was noted frequently in all groups ( 0 to 25 %), as was diarrhea ( 0 - 20 %). none of the clinical symptoms noted were pathognomic for pmws . the overall incidence of clinical symptoms varied between groups . groups receiving any of the vorf2 vaccines , the group receiving 16 μg of rorf2 , the group receiving 2 doses of kv vaccine and the challenge control group had the highest incidence of overall clinical symptoms (≧ 36 . 4 %). the strict negative control group , the group receiving 8 μg of rorf2 and the group receiving 4 μg of rorf2 had overall incidence rates of clinical symptoms of 0 %, 8 . 3 % and 9 . 1 %, respectively . overall mortality rates between groups varied as well . the group receiving 2 doses of kv vaccine had the highest mortality rate ( 16 . 7 %); while groups that received 4 μg of vorf2 , 16 μg of rorf2 , or 8 μg of rorf2 and the strict negative control group all had 0 % mortality rates . pcv2 nasal shedding results are presented below in table 11 . following challenge on day 24 , 1 pig in group 7 began shedding pcv2 on day 27 . none of the other groups experienced shedding until day 33 . the bulk of nasal shedding was noted from day 35 to day 45 . groups receiving any of the three vorf2 vaccines and groups receiving either 4 or 8 μg of rorf2 had the lowest incidence of nasal shedding of pcv2 (≦ 9 . 1 %). the challenge control group ( group 8 ) had the highest shedding rate ( 80 %), followed by the strict , negative control group ( group 9 ), which had an incidence rate of 63 . 6 %. the summary of group incidence of icterus . group incidence of gastric ulcers , group mean lung lesion scores , and group incidence of lung lesions are shown below in table 12 . six pigs died at the first test site during the post - vaccination phase of the study ( group 4 . n = 1 : group 6 , n = 1 ; group 8 , n = 2 ; group 9 , n = 2 ). four out of six pigs had fibrinous lesions in one or more body cavities , one pig ( group 6 ) had lesions consistent with clostridial disease , and one pig ( group 9 ) had no gross lesions . none of the pigs that died during the post - vaccination phased of the study had lesions consistent with pmws . pigs that died post - challenge and pigs euthanized on day 49 were necropsied . at necropsy , icterus and gastric ulcers were not present in any group . with regard to mean % lung lesions , group 9 had lowest mean % lung lesions ( 0 %), followed by group 1 with 0 . 40 ± 0 . 50 % and group 5 with 0 . 68 ± 1 . 15 %. groups 2 , 3 , 7 and 8 had the highest mean % lung lesions (≧ 7 . 27 %). each of these four groups contained one pig with % lung lesions ≧ 71 . 5 %, which skewed the results higher for these four groups . with the exception of group 9 with 0 % lung lesions noted , the remaining 8 groups had ≦ 36 % lung lesions . almost all lung lesions noted were described as red / purple and consolidated . the summary of group ihc positive incidence results are shown in table 13 . group 1 ( vorf2 - 16 μg ) and group 5 ( rorf2 - 8 μg ) had the lowest rate of ihc positive results ( 16 . 7 %), group 8 ( challenge controls ) and group 9 ( strict negative controls ) had the highest rate of ihc positive results , 90 % and 90 . 9 %, respectively . post - challenge , group 5 , which received one dose of 8 μg of rorf2 antigen , outperformed the other 6 vaccine groups . group 5 had the highest adwg ( 0 . 94 ± 0 . 22 lbs / day ), the lowest incidence of abnormal behavior ( 0 %), the second lowest incidence of cough ( 8 . 3 %), the lowest incidence of overall clinical symptoms ( 8 . 3 %), the lowest mortality rate ( 0 %), the lowest rate of nasal shedding of pcv2 ( 8 . 3 %), the second lowest rate for mean % lung lesions ( 0 . 68 ± 1 . 15 %) and the lowest incidence rate for positive tissues ( 16 . 7 %). groups receiving various levels of rorf2 antigen overall outperformed groups receiving various levels of vorf2 and the group receiving 2 doses of killed whole cell pcv2 vaccine performed the worst . tables 14 and 15 contain summaries of group post - challenge data . results of this study indicate that all further vaccine efforts should focus on a rorf2 vaccine . overall , nasal shedding of pcv2 was detected post - challenge and vaccination with a pcv2 vaccine resulted in a reduction of shedding , immunohistochemistry of selected lymphoid tissues also served as a good parameter for vaccine efficacy , whereas large differences in adwg , clinical symptoms , and gross lesions were not detected between groups . this study was complicated by the fact that extraneous pcv2 was introduced at some point during the study , as evidenced by nasal shedding of pcv2 , pcv2 seroconversion and positive ihc tissues in group 9 , the strict negative control group . seven pcv2 vaccines were evaluated in this study , which included three different dose levels of vorf2 antigen administered once on day 0 , three different dose levels of rorf2 antigen administered once on day 0 and one dose level of killed whole cell pcv2 vaccine administered on day 0 and day 14 . overall , group 5 , which received 1 dose of vaccine containing 8 μg of rorf2 antigen , had the best results . group 5 had the highest adwg , the lowest incidence of abnormal behavior , the lowest incidence of abnormal respiration , the second lowest incidence of cough , the lowest incidence of overall clinical symptoms , the lowest mortality rate , the lowest rate of nasal shedding of pcv2 , the second lowest rate for mean % lung lesions and the lowest incidence rate for positive ihc tissues . interestingly , group 4 , which received a higher dose of rorf2 antigen than group 5 , did not perform as well or better than group 5 . group 4 had a slightly lower adwg , a higher incidence of abnormal behavior , a higher incidence of overall clinical symptoms , a higher rate of nasal shedding of pcv2 , a higher mean % lung lesions , and a higher rate for positive ihc tissues than group 5 . statistical analysis , which may have indicated that the differences between these two groups were not statistically significant , was not conducted on these data , but there was an observed trend that group 4 did not perform as well as group 5 . post - vaccination , 6 pigs died at the first study site . four of the six pigs were from group 8 or group 9 , which received no vaccine . none of the six pigs demonstrated lesions consistent with pmws , no adverse events were reported and overall , all seven vaccines appeared to be safe when administered to pigs approximately 11 days of age . during the post - vaccination phase of the study , pigs receiving either of three dose levels of vorf2 vaccine or killed whole cell vaccine had the highest ifat levels , while group 5 had the lowest ifat levels just prior to challenge , of the vaccine groups . although not formally proven , the predominant route of transmission of pcv2 to young swine shortly after weaning is believed to be by oronasal direct contact and an efficacious vaccine that reduces nasal shedding of pcv2 in a production setting would help control the spread of infection . groups receiving one of three vorf2 antigen levels and the group receiving 8 μg of rorf2 had the lowest incidence rate of nasal shedding of pcv2 ( 8 . 3 %). expectedly , the challenge control group had the highest incidence rate of nasal shedding ( 80 %). gross lesions in pigs with pmws secondary to pcv2 infection typically consist of generalized lymphadenopathy in combination with one or a multiple of the following : ( 1 ) interstitial pneumonia with interlobular edema , ( 2 ) cutaneous pallor or icterus , ( 3 ) mottled atrophic livers , ( 4 ) gastric ulcers and ( 5 ) nephritis . at necropsy , icterus , hepatitis , nephritis , and gastric ulcers were not noted in any groups and lymphadenopathy was not specifically examined for . the mean % lung lesion scores varied between groups . the group receiving 16 μg of vorf2 antigen had the lowest mean % lung lesion score ( 0 . 40 ± 0 . 50 %), followed by the group that received 8 μg of rorf2 ( 0 . 68 ± 1 . 15 %). as expected , the challenge control group had the highest mean % lung lesion score ( 9 . 88 ± 29 . 2 %). in all four groups , the mean % lung lesion scores were elevated due to one pig in each of these groups that had very high lung lesion scores . most of the lung lesions were described as red / purple and consolidated . typically , lung lesions associated with pmws are described as tan and non - collapsible with interlobular edema . the lung lesions noted in this study were either not associated with pcv2 infection or a second pulmonary infectious agent may have been present . within the context of this study , the % lung lesion scores probably do not reflect a true measure of the amount of lung infection due to pcv2 . other researchers have demonstrated a direct correlation between the presence of pcv2 antigen , by ihc and histopathology . histopathology on select tissues was not conducted with this study . group 1 ( 16 μg of orf2 ) and group 5 ( 8 μg of rorf2 ) had the lowest incidence rate of pigs positive for pcv2 antigen ( 8 . 3 %), while group 9 ( the strict negative control group — 90 . 9 %) and group 8 ( the challenge control group — 90 . 0 %) had the highest incidence rates for pigs positive for pcv2 antigen . due to the non - subjective nature of this test , ihc results are probably one of the best parameters to judge vaccine efficacy on . thus , in one aspect of the present invention , the minimum portective dosage ( mpd ) of a 1 ml / l dose recombinant product with extracted pcv2 orf2 ( rorf2 ) antigen in the cdcd pig model in the face of a pcv2 challenge was determined . of the three groups that received varying levels of rorf2 antigen , group 5 ( 8 μg of rorf2 antigen ) clearly had the highest level of protection . group 5 either had the best results or was tied for the most favorable results with regard to all of the parameters examined . when group 5 was compared with the other six vaccine groups post - challenge , group 5 had the highest adwg ( 0 . 94 ± 0 . 22 lbs / day ), the lowest incidence of abnormal behavior ( 0 %), the second lowest incidence of cough ( 8 . 3 %), the lowest incidence of overall clinical symptoms ( 8 . 3 %), the lowest mortality rate ( 0 %), the lowest rate of nasal shedding of pcv2 ( 8 . 3 %), the second lowest rate for mean % lung lesions ( 0 . 68 ± 1 . 15 %) and the lowest incidence rate for positive ihc tissues ( 16 . 7 %). in another aspect of the present invention , the mpd of a 1 ml / l dose conventional product that is partially purified pcv2 orf2 ( vorf2 ) antigen in the cdcd pig model in the face of a pcv2 challenge was determined . of the three groups that received varying levels of vorf2 antigen . group 1 ( 16 μg of vorf2 ) had the highest level of protection . group 1 outperformed groups 2 and 3 with respect to adwg , mean % lung lesions , and ihc . groups 1 and 2 ( 8 μg of vorf2 antigen ) performed equally with respect to overall incidence of clinical symptoms , group 3 ( 4 μg of vorf2 antigen ) had the lowest mortality rate , and all three groups performed equally with respect to nasal shedding . overall , vorf vaccines did not perform as well as rorf vaccines . in yet another aspect of the present invention , the efficacy of a maximum dose of a 2 ml / 2 dose conventional killed pcv2 vaccine in the cdcd pig model in the face of a pcv2 challenge was determined . of the seven vaccines evaluated in this study , the killed whole cell pcv2 vaccine performed the worst . piglets receiving two doses of killed whole cell pcv2 vaccine had the lowest adwg , the second highest rate of abnormal behavior ( 58 . 3 %), the second highest overall incidence of clinical symptoms ( 58 . 3 %), the highest mortality rate ( 16 . 7 %), the second highest , incidence of nasal shedding ( 41 . 7 %), highest mean % lung lesions ( 9 . 88 ± 29 . 2 %), a high incidence of lung lesions noted ( 75 %) and a moderate ihc incidence rate in tissues ( 41 . 7 %). however , it was still effective at invoking an immune response . in still another aspect of the present invention , nasal shedding of pcv2 was assessed as an efficacy parameter and the previous pcv2 efficacy parameters from previous studies were reconfirmed . results from this study indicate that nasal shedding of pcv2 occurs following intra nasal challenge and that pcv2 vaccines reduce nasal shedding of pcv2 post - challenge . furthermore , results from this study and reports in the literature indicate that ihc should continue to be evaluated in future pcv2 vaccine trials as well . some additional conclusions arising from this study are that lymphadenopathy is one of the hallmarks of pmws . another one of the hallmarks of pmws is lymphoid depletion and multinucleated / giant histiocytes . additionally , no adverse events or injection site reactions were noted for any of the 7 pcv2 vaccines and all 7 pcv2 vaccines appeared to be safe when administered to young pigs . this example tests the efficacy of eight pcv2 candidate vaccines and reconfirms pcv2 challenge parameters from earlier challenge studies following exposure to a virulent strain of pcv2 . one hundred and fifty ( 150 ) cesarean derived colostrum deprived ( cdcd ) piglets , 6 - 16 days of age , were blocked by weight and randomly divided into 10 groups of equal size . table 16 sets forth the general study design for this example . the vaccine formulation given to each group was as follows . pcv2 vaccine no . 1 , administered at 1 × 2 ml dose to group 1 , was a high dose ( 16 μg / 2 ml dose ) of inactivated recombinant orf2 antigen adjuvanted with ims 1314 ( 16 μg rorf2 — ims 1314 ). pcv2 vaccine no . 2 , administered at 1 × 2 ml dose to group 2 , was a high dose ( 16 ug / 2 ml dose ) of a partially purified vido r - 1 generated pcv2 orf2 antigen adjuvanted with carbopol ( 16 ug vorf2 — carbopol ). pcv2 vaccine no . 3 , administered at 1 × 2 ml dose to group 3 , was a high dose ( 16 ug / 2 ml dose ) of inactivated recombinant orf2 antigen adjuvanted with carbopol ( 16 ug rorf2 — carbopol ). pcv2 vaccine no . 4 , administered at 1 × 1 ml dose to group 4 , was a high dose ( 16 ug / 1 ml dose ) of a partially purified vido r - 1 generated pcv2 orf2 antigen adjuvanted with carbopol ( 16 ug vorf2 — carbopol ). vaccine no . 5 , administered at 1 × 2 ml dose to group 5 , was a 4 ug / 2 ml dose of an inactivated recombinant orf2 antigen adjuvanted with carbopol ( 4 ug rorf2 — carbopol ). pcv2 vaccine no . 6 , administered at 1 × 2 ml dose to group 6 , was a 1 ug / 2 ml dose of an inactivated recombinant orf2 antigen adjuvanted with carbopol ( 1 ug rorf2 — carbopol ). pcv2 vaccine no . 7 , administered at 1 × 2 ml dose to group 7 , was a low dose ( 0 . 25 ug / 2 ml dose ) of inactivated recombinant orf2 antigen adjuvanted with carbopol ( 0 . 25 ug rorf2 — carbopol ). pcv2 vaccine no . 8 , administered at 1 × 2 ml dose to group 8 , was a high dose ( pre - inactivation titer & gt ; 8 . 0 log / 2 ml dose ) inactivated conventional killed vido r - 1 generated pcv2 struve antigen adjuvanted with carbopol (& gt ; 8 . 0 log kv - carbopol ). on day 0 , groups 1 - 8 were treated with their assigned vaccines . groups 1 - 3 and 5 - 8 received boosters of their respective vaccines again on day 14 . the effectiveness of a single dose of 16 μg of vorf2 - carbopol was tested on group 4 which did not receive a booster on day 14 . piglets were observed for adverse events and injection site reactions following both vaccinations . on day 21 the piglets were moved to a second study site where groups 1 - 9 were group housed in one building and group 10 was housed in a separate building . all pigs received keyhole limpet hemocyanin emulsified with incomplete freund &# 39 ; s adjuvant ( klh / icfa ) on days 22 and 28 . on day 25 , groups 1 - 9 were challenged with approximately 4 logs of virulent pcv2 virus . by day 46 , very few deaths had occurred in the challenge control group . in an attempt to immunostimulate the pigs and increase the virulence of the pcv2 challenge material , all groups were treated with ingelvac ® prrsv mlv ( porcine reproductive and respiratory vaccine , modified live virus ) on day 46 . pre - and post - challenge blood samples were collected for pcv2 serology . post - challenge , body weight data for determination of average daily weight gain ( adwg ) and observations of clinical signs were collected . on day 50 , all surviving pigs were necropsied , gross lesions were recorded , lungs were scored for pathology , and selected tissues were preserved in formalin for examination by immunohistochemistry ( ihc ) for detection of pcv2 antigen at a later date . this was a partially - blind vaccination - challenge feasibility study conducted in cdcd pigs , 6 to 16 days of age on day 0 . to be included in the study , pcv2 ifa titers of sows were ≦ 1 : 1000 . additionally , the serologic status of sows were from a known prrs - negative herd . sixteen ( 16 ) sows were tested for pcv2 serological status and all sixteen ( 16 ) had a pcv2 titer of ≦ 1000 and were transferred to the first study site . one hundred fifty ( 150 ) piglets were delivered by cesarean section surgeries and were available for this study on . day − 3 . on day − 3 , 150 cdcd pigs at the first study site were weighed , identified with ear tags , blocked by weight and randomly assigned to 1 of 10 groups , as set forth above in table 16 . blood samples were collected from all pigs . if any test animal meeting the inclusion criteria was enrolled in the study and was later excluded for any reason , the investigator and monitor consulted in order to determine the use of data collected from the animal in the final analysis . the date of which enrolled piglets were excluded and the reason for exclusion was documented . no sows meeting the inclusion criteria selected for the study and transported to the first study site were excluded . no piglets were excluded from the study , and no test animals were removed from the study prior to termination . table 17 describes the time frames for the key activities of this example . following completion of the in - life phase of the study , formalin fixed tissues were examined by immunohistochemistry ( ihc ) for detection of pcv2 antigen by a pathologist , blood samples were evaluated for pcv2 serology , and average daily weight gain ( adwg ) was determined from day 25 to day 50 . animals were housed at the first study site in individual cages in seven rooms from birth to approximately 11 days of age ( approximately day 0 of the study ). each room was identical in layout and consisted of stacked individual stainless steel cages with heated and filtered air supplied separately to each isolation unit . each room had separate heat and ventilation , thereby preventing cross - contamination of air between rooms . animals were housed in two different buildings at the second study site . group 10 ( the strict negative control group ) was housed separately in a converted nursery building and groups 1 - 9 were housed in a converted farrowing building . each group was housed in a separate pen ( 14 - 15 pigs per pen ) and each pen provided approximately 2 . 3 square feet per pig . groups 2 , 4 and 8 were penned in three adjacent pens on one side of the alleyway and groups 1 , 3 , 5 , 6 , 7 , and 9 were penned in six adjacent pens on the other side of the alleyway . the group separation was due to concern by the study monitor that vaccines administered to groups 2 , 4 , and 8 had not been fully inactivated . each pen was on an elevated deck with plastic slatted , floors . a pit below the pens served as a holding tank for excrement and waste . each building had its own separate heating and ventilation systems , with little likelihood of cross - contamination of air between buildings . at the first study site , piglets were fed a specially formulated milk ration from birth to approximately 3 weeks of age . all piglets were consuming solid , special mixed ration by day 21 ( approximately 4½ weeks of age ). at the second study site , all piglets were fed a custom non - medicated commercial mix ration appropriate for their age and weight , ad libitum . water at both study sites was also available ad libitum . all test pigs were treated with 1 . 0 ml of naxcel ®, 1m , in alternating hams on days 19 , 20 , and 21 . in addition . pig no . 11 ( group 1 ) was treated with 0 . 5 ml , of naxcel ® 1m on day 10 . pig no . 13 ( group 10 ) was treated with 1 ml of penicillin and 1 ml of predef ® 2 × on day 10 , pig no . 4 ( group 9 ) was treated with 1 . 0 ml of naxcel ® 1m on day 11 , and pigs 1 ( group 1 ), 4 and 11 were each treated with 1 . 0 ml of naxcel ® on day 14 for various health reasons . while at both study sites , pigs were under veterinary care . animal health examinations were conducted on day − 3 and were recorded on the health examination record form . all animals were in good health and nutritional status before vaccination as determined by observation on day 0 . all test animals were observed to be in good health and nutritional status prior to challenge . carcasses and tissues were disposed of by rendering . final disposition of study animals was recorded on the animal disposition record . on days 0 and 14 , pigs assigned to groups 1 - 3 and 5 - 8 received 2 . 0 ml of assigned pcv2 vaccines 1 - 4 , respectively , 1m in the right and left neck region , respectively , using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × w needle . pigs assigned to group 4 received 1 . 0 ml of pcv2 vaccine no . 2 , 1m in the right neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × w needle on day 0 only . on day 22 all test pigs received 2 . 0 ml , of klh / icfa 1m in the left neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × 1 ″ needle . on day 28 ail test pigs received 2 . 0 ml , of klh / icfa in the right ham region using a sterile 3 . 0 ml , luer - lock syringe and a sterile 20 g × 1 ″ needle . on day 25 , pigs assigned to groups 1 - 9 received 1 . 0 ml of pcv2 isuvdl challenge material ( 3 . 98 log 10 tcid 50 / ml ) 1m in the right neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × 1 ″ needle . an additional 1 . 0 ml of the same material was administered 1n to each pig ( 0 . 5 ml per nostril ) using a sterile 3 . 0 ml luer - lock syringe and nasal canula . on day 46 , all test pigs received 2 . 0 ml ingelvac ® prrs mlv , 1m , in the right neck region using a sterile 3 . 0 ml luer - lock syringe and a sterile 20 g × 1 ″ needle . the prrsv mlv was administered in an attempt to increase virulence of the pcv2 challenge material . test pigs were observed daily for overall health and adverse events on day − 3 and from day 0 to day 21 . each of the pigs was scored for normal or abnormal behavior , respiration or cough . observations were recorded on the clinical observation record . all test pigs were observed from day 0 to day 7 , and group 7 was further observed from day 14 to 21 , for injection site reactions . average daily weight gain was determined by weighing each pig on a calibrated scale on days − 3 , 25 and 50 , or on the day that a pig was found dead after challenge . body weights were recorded on the body weight form . day − 3 body weights were utilized to block pigs prior to randomization . day 25 and day 50 weight data was utilized to determine the average daily weight gam ( adwg ) for each pig during these time points . for pigs that died after challenge and before day 50 , the adwg was adjusted to represent the adwg from day 25 to the day of death . in order to determine pcv2 serology , venous whole blood was collected from each piglet from the orbital venous sinus on days − 3 and 14 . for each piglet , blood was collected from the orbital venous sinus by inserting a sterile capillary tube into the medial canthus of one of the eyes and draining approximately 3 . 0 ml , of whole blood into a 4 . 0 ml . serum separator tube ( sst ). on days 25 , 32 , and 50 , venous whole blood from each pig was collected from the anterior vena cava using a sterile 20 g × 1½ ″ vacutainer ® needle ( becton dickinson and company , franklin lakes , n . j . ), a vaccutainer ® needle holder and a 13 ml sst . blood collections at each time point were recorded on the sample collection record . blood in each sst was allowed to clot , each sst was then spun down and the serum harvested . harvested serum was transferred to a sterile snap tube and stored at − 70 ± 10 ° c . until tested at a later date . serum samples were tested for the presence of pcv2 antibodies by bivi - r & amp ; d personnel . pigs were observed once daily from day 22 to day 50 for clinical symptoms and scored for normal or abnormal behavior , respiration or cough . clinical observations were recorded on the clinical observation record . pigs nos . 46 ( group 1 ) and 98 ( groups 9 ) died at the first study site . both of these deaths were categorized as bleeding deaths and necropsies were not conducted on these two pigs . at the second study site , pigs that died after challenge and prior to day 50 , and pigs euthanized on day 50 , were necropsied . any gross lesions were noted and the percentages of lung lobes with lesions were recorded on the necropsy report form . from each of the pigs necropsied at the second study site , a tissue sample of tonsil , lung , heart , and mesenteric lymph node was placed into a single container with buffered 10 % formalin : while another tissue sample from the same aforementioned organs was placed into a whirl - pak ® ( m - tech diagnostics ltd ., thelwall , uk .) and each whirl - pak ® was placed on ice . each container was properly labeled . sample collections were recorded on the necropsy report form . afterwards , formalin - fixed tissue samples and a diagnostic request form were submitted for ihc testing . ihc testing was conducted in accordance with standard laboratory procedures for receiving samples , sample and slide preparation , and staining techniques . fresh tissues in whirl - paks ® were shipped with ice packs to the study monitor for storage (− 70 °± 10 ° c .) and possible future use . formalin - fixed tissues were examined by a pathologist for detection of pcv2 by ihc and scored using the following scoring system : 0 = none ; 1 = scant positive staining , few sites ; 2 = moderate positive staining , multiple sites ; and 3 = abundant positive staining , diffuse throughout the tissue . for analytical purposes , a score of 0 was considered “ negative ,” and a score of greater than 0 was considered “ positive .” results for this example are given below . it is noted that pigs no . 46 and 98 died on days 14 and 25 respectively . these deaths were categorized as bleeding deaths . pig no . 11 ( group 1 ) was panting with rapid respiration on day 15 . otherwise , all pigs were normal for behavior , respiration and cough during this observation period and no systemic adverse events were noted with any groups . no injection site reactions were noted following vaccination on day 0 . following vaccination on day 14 , seven ( 7 ) out of fourteen ( 14 ) group 1 pigs ( 50 . 0 %) had swelling with a score of “ 2 ” on day 15 . four ( 4 ) out of fourteen ( 14 ) group 1 ( 28 . 6 %) still had a swelling of “ 2 ” on day 16 . none of the other groups experienced injection site reactions following either vaccination . average daily weight gain ( adwg ) results are presented below in table 18 . pigs no . 46 and 98 that died from bleeding were excluded from group results . group 4 , which received one dose of 16 ug vorf2 — carbopol had the highest adwg ( 1 . 16 ± 0 . 26 lbs / day ), followed by groups 1 , 2 , 3 , 5 , 6 , and 10 which had adwgs that ranged from 1 . 07 ± 0 . 23 lbs / day to 1 . 11 ± 0 . 26 lbs / day . group 9 had the lowest adwg ( 0 . 88 ± 0 . 29 lbs / day ), followed by groups 8 and 7 , which had adwgs of 0 . 93 ± 0 . 33 lbs / day and 0 . 99 ± 0 . 44 lbs / day , respectively . pvc2 serology results are presented below in table 19 . all ten ( 10 ) groups were seronegative for pcv2 on day − 3 . on day 14 , pcv2 titers remained low for all ten ( 10 ) groups ( range of 50 - 113 ). on day 25 , group 8 , which received the whole cell killed virus vaccine , had the highest pcv2 titer ( 4617 ), followed by group 2 , which received 16 ug vorf2 — carbopol , group 4 , which received as single dose of 16 ug vorf2 — carbopol , and group 3 , which received 16 ug rorf2 — carbopol which had titers of 2507 , 1920 and 1503 respectively . on day 32 ( one week post challenge ), titers for groups 1 - 6 and group 8 ranged from 2360 to 7619 ; while groups 7 ( 0 . 25 ug rorf2 — carbopol ), 9 ( challenge control ), and 10 ( strict negative control ) had titers of 382 , 129 and 78 respectively . on day 50 ( day of necropsy ), all ten ( 10 ) groups demonstrated high pcv2 titers (≧ 1257 ). on days 25 , 32 , and 50 , group 3 , which received two doses of 16 ug rorf2 - carbopol had higher antibody titers than group 1 , which received two doses of 16 ug rorf2 — ims 1314 . on days 25 , 32 and 50 , group 2 , which received two doses of 16 ug vorf2 had higher titers than group 4 , which received only one does of the same vaccine . groups 3 , 5 , 6 , 7 , which received decreasing levels of rorf2 — carbopol , of 16 , 4 , 1 , and 0 . 25 ug respectively , demonstrated correspondingly decreasing antibody titers on days 25 and 32 . the results from the post - challenge clinical observations are presented below . table includes observations for abnormal behavior , abnormal respiration , cough and diarrhea . table 21 includes the results from the summary of group overall incidence of clinical symptoms and table 22 includes results from the summary of group mortality rates post - challenge . the incidence of abnormal behavior , respiration and cough post - challenge were low in pigs receiving 16 ug rorf2 - ims 1314 ( group 1 ), 16 ug rorf2 - carbopol ( group 3 ), 1 ug rorf2 - carbopol ( group 6 ), 0 . 25 ug rorf2 - carbopol ( group 7 ), and in pigs in the challenge control group ( group 9 ). the incidence of abnormal behavior respiration and cough post - challenge was zero in pigs receiving 16 ug vorf2 - carbopol ( group 2 ), a single dose of 16 ug vorf2 - carbopol ( group 4 ), 4 ug rorf2 - carbopol ( group 5 ), & gt ; 8 log kv - carbopol ( group 8 ), and in pigs in the strict negative control group ( group 10 ). the overall incidence of clinical symptoms varied between groups . pigs receiving 16 ug vorf2 - carbopol ( group 2 ), a single dose of 16 ug vorf2 - carbopol ( group 4 ), and pigs in the strict negative control group ( group 10 ) had incidence rates of 0 %; pigs receiving 16 ug rorf2 - carbopol ( group 3 ), and 1 ug rorf2 - carbopol ( group 6 ) had incidence rates of 6 . 7 %; pigs receiving 16 ug rorf2 - ims 1314 ( group 1 ) had an overall incidence rate of 7 . 1 %; pigs receiving 4 ug rorf2 - carbopol ( group 5 ), 0 . 25 ug rorf2 - carbopol ( group 7 ), and & gt ; 8 log kv vaccine had incidence rates of 13 . 3 %; and pigs in the challenge control group ( group 9 ) had an incidence rate of 14 . 3 %. overall mortality rates between groups varied as well . group 8 , which received 2 doses of kv vaccine had the highest mortality rate of 20 . 0 %; followed by group 9 , the challenge control group , and group 7 , which received 0 . 25 ug rorf2 - carbopol and had mortality rates of 14 . 3 % and 13 . 3 % respectively . group 4 , which received one dose of 16 ug orf2 - carbopol had a 6 . 7 % mortality rate . all of the other groups , 1 , 2 , 3 , 5 , 6 , and 10 had a 0 % mortality rate . the summary of group mean percentage lung lesions and tentative diagnosis is given below in table 23 . group 9 , the challenge control group , had the highest percentage lung lesions with a mean of 10 . 81 ± 23 . 27 %, followed by group 7 , which received 0 . 25 ug rorf2 - carbopol and had a mean of 6 . 57 ± 24 . 74 %, group 5 , which received 4 ug rorf2 - carbopol and had a mean of 2 . 88 ± 8 . 88 %, and group 8 , which received the kv vaccine and had a mean of 2 . 01 ± 4 . 98 %. the remaining six ( 6 ) groups had lower mean percentage lung lesions that ranged from 0 . 11 ± 0 . 38 % to 0 . 90 ± 0 . 15 %. tentative diagnosis of pneumonia varied among the groups . group 3 , which received two doses of 16 ug rorf2 - carbopol had the lowest tentative diagnosis of pneumonia , with 13 . 3 %. group 9 , the challenge control group , had 50 % of the group tentatively diagnosed with pneumonia , followed by group 10 , the strict negative control group and group 2 , which received two doses of 16 ug vorf2 - carbopol , with 46 . 7 % of 40 % respectively , tentatively diagnosed with pneumonia . groups 1 , 2 , 3 , 5 , 9 , and 10 had 0 % of the group tentatively diagnosed as pcv2 infected ; while group 8 , which received two doses if kv vaccine , had the highest group rate of tentative diagnosis of pcv2 infection , which 20 %. group 7 , which received two doses of 0 . 25 ug rorf2 - carbopol , and group 4 , which received one dose of 16 ug vorf2 - carbopol had tentative group diagnoses of pcv2 infection in 13 . 3 % and 6 . 7 % of each group , respectively . gastric ulcers were only diagnosed in one pig in group 7 ( 6 . 7 %); while the other 9 groups remained free of gastric ulcers . the summary of group ihc positive incidence results are shown below in table 24 , group 1 ( 16 ug rorf2 — ims 1314 ) had the lowest group rate of ihc positive results with 0 % of the pigs positive for pcv2 , followed by group 2 ( 16 ug vorf2 — carbopol ) and group 4 ( single dose 16 ug vorf2 carbopol ), which had group imc rates of 6 . 7 % and 13 . 3 % respectively . group 9 , the challenge control group , had the highest ihc positive incidence rate with 100 % of the pigs positive for pcv2 , followed by group 10 , the strict negative control group , and group 8 ( kv vaccine ), with 93 . 3 % and 80 % of the pigs positive for pcv2 , respectively . seven pcv2 vaccines were evaluated in this example , which included a high dose ( 16 μg ) of rorf2 antigen adjuvanted with ims 13 . 14 administered twice , a high dose ( 16 μg ) of vorf2 antigen adjuvanted with carbopol administered once to one group of pigs and twice to a second group of pigs , a high dose ( 16 μg ) of rorf2 antigen adjuvanted with carbopol administered twice , a 4 μg dose of rorf2 antigen adjuvanted with carbopol administered twice , a 1 μg dose of rorf2 antigen adjuvanted with carbopol administered twice , a low dose ( 0 . 25 μg ) of rorf2 antigen adjuvanted with carbopol administered twice , and a high dose (& gt ; 8 log ) of killed whole cell pcv2 vaccine adjuvanted with carbopol . overall , group 1 , which received two doses of 16 μg rorf2 - ims 1314 , performed slightly better than groups 2 through 7 , which received vaccines containing various levels of either vorf2 or rorf2 antigen adjuvanted with carbopol and much better than group 8 , which received two doses of killed whole cell pcv2 vaccine . group 1 had the third highest adwg ( 1 . 80 ± 0 . 30 lbs / day ), the lowest incidence of abnormal behavior ( 0 %), the lowest incidence of abnormal respiration ( 0 %), a low incidence of cough ( 7 . 1 %), a low incidence of overall clinical symptoms ( 7 . 1 %), was tied with three other groups for the lowest mortality rate ( 0 %), the second lowest rate for mean % lung lesions ( 0 . 15 ± 0 . 34 %), the second lowest rate for pneumonia ( 21 . 4 %) and the lowest incidence rate for positive ihc tissues ( 0 %). group 1 was , however , the only group in which injection site reactions were noted , which included 50 % of the vaccinates 1 day after the second vaccination . the other vaccines administered to groups 2 through 7 performed better than the killed vaccine and nearly as well as the vaccine administered to group 1 . group 8 , which received two doses of killed pcv2 vaccine adjuvanted with carbopol , had the worst set of results for any vaccine group . group 8 had the lowest adwg ( 0 . 93 ± 0 . 33 lbs / day ), the second highest rate of abnormal behavior ( 6 . 7 %), the highest rate of abnormal respiration ( 6 . 7 %), was tied with three other groups for the highest overall incidence rate of clinical symptoms ( 13 . 3 %), had the highest mortality rate of all groups ( 20 %), and had the highest positive ihc rate ( 80 %) of any vaccine group . there was concern that the killed whole cell pcv2 vaccine may not have been fully inactivated prior to administration to group 8 , which may explain this group &# 39 ; s poor results . unfortunately , definitive data was not available to confirm this concern . overall in the context of this example , a conventional killed pcv2 vaccine did not aid in the reduction of pcv2 associated disease . as previously mentioned , no adverse events were associated with the test vaccines with exception of the vaccine adjuvanted with ims 1314 . injection site reactions were noted in 50 . 0 % of the pigs 1 day after the second vaccination with the vaccine formulated with ims 1314 and in 28 . 6 % of the pigs 2 days after the second vaccination . no reactions were noted in any pigs receiving carbopol adjuvanted vaccines . any further studies that include pigs vaccinated with ims 1314 adjuvanted vaccines should continue to closely monitor pigs for injection site reactions . all pigs were sero - negative for pcv2 on day − 3 and only group 2 had a titer above 100 on day 14 . on day 25 ( day of challenge ). group 8 had the highest pcv2 antibody titer ( 4619 ), followed by group 2 ( 2507 ). with the exception of groups 7 , 9 and 10 , all groups demonstrated a strong antibody response by day 32 . by day 50 , all groups including groups 7 , 9 and 10 demonstrated a strong antibody response . one of the hallmarks of late stage pcv2 infection and subsequent pmws development is growth retardation in weaned pigs , and in severe cases , weight loss is noted . average daily weight gain of groups is a quantitative method of demonstrating growth retardation or weight loss . in this example , there was not a large difference in adwg between groups . group 8 had the lowest adwg of 0 . 88 ± 0 . 29 lbs / day , while group 4 had the highest adwg of 1 . 16 ± 0 . 26 lb / day . within the context of thus study there was not a sufficient difference between groups to base future vaccine efficacy on adwg . in addition to weight loss — dyspnea , lethargy , pallor of the skin and sometimes icterus are clinical symptoms associated with pmws . in this example , abnormal behavior and abnormal respiration and cough were noted infrequently for each group . as evidenced in this study , this challenge model and challenge strain do not result in overwhelming clinical symptoms and this is not a strong parameter on which to base vaccine efficacy . overall , mortality rates were not high in this example and the lack of a high mortality rate in the challenge control group limits this parameter on which to base vaccine efficacy . prior to day 46 , groups 4 and 7 each had one out of fifteen pigs die . group 9 had two out of fourteen pigs die and group 8 had three out of fifteen pigs die . due to the fact that group 9 , the challenge control group was not demonstrating pcv2 clinical symptoms and only two deaths had occurred in this group by day 46 , porcine respiratory and reproductive syndrome virus ( prrsv ) mlv vaccine was administered to all pigs on day 46 . earlier studies had utilized ingelvac ® prrs mlv as an immunostimulant to exasperate pcv 2 - associated pmws disease and mortality rates were higher in these earlier studies . two deaths occurred shortly after administering the prrs vaccine on day 46 — group 4 had one death on day 46 and group 7 had one death on day 47 — which were probably not associated with the administration of the prrs vaccine . by day 50 , group 8 , which received two doses of killed vaccine , had the highest mortality rate ( 20 %), followed by group 9 ( challenge control ) and group 7 ( 0 . 25 ug rorf2 — carbopol ), with mortality rates of 14 . 3 % and 13 . 3 % respectively . overall , administration of the prrs vaccine to the challenge model late in the post - challenge observation phase of this example did not significantly increase mortality rates . gross lesions in pigs with pmws secondary to pcv2 infection typically consist of generalized lymphadenopathy in combination with one or more of the following : ( 1 ) interstitial pneumonia with interlobular edema , ( 2 ) cutaneous pallor or icterus , ( 3 ) mottled atrophic livers , ( 4 ) gastric ulcers and ( 5 ) nephritis . at necropsy ( day 50 ), icterus , hepatitis , and nephritis were not noted in any groups . a gastric ulcer was noted in one group 7 pig , but lymphadenopathy was not specifically examined for . based on the presence of lesions that were consistent with pcv2 infection , three groups had at least one pig tentatively diagnosed with pcv2 ( pmws ). group 8 , which received two doses of killed vaccine , had 20 % tentatively diagnosed with pcv2 , while group 7 and group 4 had 13 . 3 % and 6 . 7 %, respectively , tentatively diagnosed with pcv2 . the mean % lung lesion scores varied between groups at necropsy . groups 1 , 2 , 3 , 4 , 6 and 10 had low % lung lesion scores that ranged from 0 . 11 ± 0 . 38 % to 0 . 90 ± 0 . 15 %. as expected , group 9 , the challenge control group , had the highest mean % lung lesion score ( 10 . 81 ± 23 . 27 %). in four groups , the mean % lung lesion scores were elevated due to one to three pigs in each of these groups having very high lung lesion scores . the lung lesions were red / purple and consolidated . typically , lung lesions associated with pmws are described as tan , non - collapsible with interlobular edema . the lung lesions noted in this study were either not associated with pcv2 infection or a second pulmonary infectious agent may have been present . within the context of this study , the % lung lesion scores probably do not reflect a true measure of the amount of lung infection due to pcv2 . likewise , tentative diagnosis of pneumonia may have been over - utilized as well . any pigs with lung lesions , some as small as 0 . 10 % were listed with a tentative diagnosis of pneumonia . in this example , there was no sufficient difference between groups with respect to gross lesions and % lung lesions on which to base vaccine efficacy . ihc results showed the largest differences between groups . group 1 ( 16 μg rorf2 — ims 13 . 14 ) had the lowest positive ihc results for pcv2 antigen ( 0 %); while groups 9 and had the highest positive ihc results with incidence rates of 100 % and 93 . 3 % respectively . groups 3 , 5 , 6 and 7 , which received 16 , 4 , 1 or 0 . 25 μg of rorf2 antigen , respectively , adjuvanted with carbopol , had ihc positive rates of 20 %, 20 %, 40 % and 46 . 7 %, respectively . group 2 , which received two doses of 16 μg vorf2 adjuvanted with carbopol had an ihc positive rate of 6 . 7 %, while group 4 which received only one dose of the same vaccine , had an ihc positive rate of 13 . 3 %. due to the objective nature of this test and the fact that ihc results correlated with expected results , ihc testing is probably one of the best parameters on which to base vaccine efficacy . thus in one aspect of the present invention , the minimum protective dosage ( mpd ) of pcv2 rorf2 antigen adjuvanted with carbopol in the cdcd pig model in the face of a pcv2 challenge is determined groups 3 , 5 , 6 and 7 each received two doses of rorf2 antigen adjuvanted with carbopol , but the level of rorf2 antigen varied for each group . groups 3 , 5 , 6 and 7 each received 16 , 4 , 1 or 0 . 25 μg of rorf2 antigen respectively . in general , decreasing the level of rorf2 antigen decreased pcv2 antibody titers , and increased the mortality rate , mean % lung lesions and the incidence of ihc positive tissues . of the lour groups receiving varying levels of rorf2 — carbopol , groups 3 and 5 , which received two doses of 16 or 4 μg of rorf2 antigen , respectively , each had an ihc positive rate of only 20 %, and each had similar antibody titers . overall , based on ihc positive results , the minimum protective dosage of rorf2 antigen administered twice is approximately 4 μg . in another aspect of the present invention , the antigenicity of recombinant ( rorf2 ) and vido r - 1 ( vorf2 ) pcv2 antigens were assessed . group 2 received two doses of 16 μg vorf2 and group 3 received two doses of 16 μg rorf2 , both vaccines were adjuvanted with carbopol . both vaccines were found to be safe and both had 0 % mortality rate . group 2 had a pcv2 antibody titer of 2507 on day 25 , while group 3 had a pcv2 antibody titer of 1503 . group 3 had a lower mean % lung lesion score than group 2 ( 0 . 11 ± 0 . 38 % vs . 0 . 90 ± 0 . 15 %), but group 2 had a lower ihc positive incidence rate that group 3 ( 6 . 7 % vs . 20 %). overall , both vaccines had similar antigenicity , but vorf2 was associated with slightly better ihc results . in yet another aspect , of the present invention , the suitability of two different adjuvants ( carbopol and ims 1314 ) was determined . groups 1 and 3 both received two doses of vaccine containing 16 ug of rorf2 antigen , but group 1 received the antigen adjuvanted with ims 1314 while group 3 received the antigen adjuvanted with carbopol . both groups had essentially the same adwg , essentially the same incidence of clinical signs post - challenge , the same mortality rate , and essentially the same mean % lung lesions ; but group 1 had an ihc positive rate of 0 % while group 3 had an ihc positive rate of 20 %. however , group 3 , which received the vaccine adjuvanted with carbopol had higher ifat pcv2 titers on days 25 , 32 and 50 than group 1 , which received the vaccine adjuvanted with ims 1314 . overall , although the pcv2 vaccine adjuvanted with ims 1314 did provide better ihc results , it did not provide overwhelmingly better protection from pcv2 infection and did induce injection site reaction . whereas the pcv2 vaccine adjuvanted with carbopol performed neatly as well as the ims 1314 adjuvanted vaccine , but was not associated with any adverse events . in still another aspect of the present invention , the feasibility of pcv2 orf2 as a 1 ml , 1 dose product was determined . groups 2 and 4 both received 16 μg of vorf2 vaccine adjuvanted with carbopol on day 0 , but group 2 received a second dose on day 14 . group 4 had a slightly higher adwg and a lower mean % lung lesions than group 2 , but group 2 had higher ifat pcv2 titers on day 25 , 32 and 50 , and a slightly lower incidence rate of ihc positive tissues . all other results for these two groups were similar . overall , one dose of vorf2 adjuvanted with carbopol performed similar to two doses of the same vaccine .
an improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided . also provided is recombinant pcv2 orf2 protein , and immunogenic compositions comprising pcv2 orf2 protein . moreover , multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of pcv2 infection , preferably pcv2 orf2 protein , or an immunogenic composition comprising pcv2 orf2 protein , and at least one immunogenic active component of another disease - causing organism in swine ,